Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

PF-07284892

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Pfizer

Drug class:

PTPN11 inhibitor

Related drugs:

EML4-ALK fusion + ALK G1202R	Non Small Cell Lung Cancer	EML4-ALK fusion + ALK G1202R	Non Small Cell Lung Cancer	lorlatinib + PF-07284892 Sensitive: C4 – Case Studies lorlatinib + PF-07284892 Sensitive : C4	lorlatinib + PF-07284892 Sensitive: C4 – Case Studies lorlatinib + PF-07284892 Sensitive : C4
BRAF V600E	Colorectal Cancer	BRAF V600E	Colorectal Cancer	cetuximab + encorafenib + PF-07284892 Sensitive: C4 – Case Studies cetuximab + encorafenib + PF-07284892 Sensitive : C4	cetuximab + encorafenib + PF-07284892 Sensitive: C4 – Case Studies cetuximab + encorafenib + PF-07284892 Sensitive : C4
GOPC-ROS1 fusion + CTNNB1 S45F	Pancreatic Adenocarcinoma	GOPC-ROS1 fusion + CTNNB1 S45F	Pancreatic Adenocarcinoma	lorlatinib + PF-07284892 Sensitive: C4 – Case Studies lorlatinib + PF-07284892 Sensitive : C4	lorlatinib + PF-07284892 Sensitive: C4 – Case Studies lorlatinib + PF-07284892 Sensitive : C4
KRAS G12D	Ovarian Serous Adenocarcinoma	KRAS G12D	Ovarian Serous Adenocarcinoma	binimetinib + PF-07284892 Sensitive: C4 – Case Studies binimetinib + PF-07284892 Sensitive : C4	binimetinib + PF-07284892 Sensitive: C4 – Case Studies binimetinib + PF-07284892 Sensitive : C4